Company intelligence / Profile preview

Liquid Mine

Ownership: Private
Development stage: Commercial

Overview

Liquid Mine has developed a proprietary liquid biopsy-based diagnostic platform called MyRD, which enables early detection of leukemia recurrence through minimally invasive blood tests. The company leverages gene analysis technology originating from the Institute of Medical Science at the University of Tokyo. Clinical results are not detailed publicly, but the company is focused on improving survival rates by enabling earlier intervention for leukemia patients.

Therapeutic areas: Oncology
Modalities: Diagnostic testLiquid biopsyGene analysis technology
Industry: Molecular Diagnostics

Partnerships

Plug and Play Ventures (investor/accelerator partnership)collaborations with academic institutions such as the Institute of Medical Science at the University of Tokyo

Beyond the preview

Go deeper on Liquid Mine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liquid Mine.

Explore the full profile